Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 7 of 6351
-
Can engineered immune cells stop a rare muscle disease?
Cure Not yet recruitingThis is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.
Phase 1/2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
A pill after transplant: new hope to stop t-cell cancer relapse
Disease control Not yet recruitingThis study evaluates whether chidamide maintenance therapy can effectively reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL). Chidami…
Phase 3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted pill boost lung cancer treatment?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a One-Time gene therapy stop the march of dry AMD?
Disease control Recruiting nowThis study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Phase 3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can stem cells restore vision in stargardt disease? a First-in-Human trial aims to find out
Cure Recruiting nowMacular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die o…
Phase 1 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
CRISPR injection could rewrite the future of blood pressure control
Disease control Recruiting nowA Study of CTX340 in Participants with Uncontrolled Hypertension.
Phase 1/2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a single Gene-Editing injection stop a blinding corneal disease?
Cure Not yet recruitingThe goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
Phase 1/2 • Sponsor: GenEditBio Limited • Aim: Cure
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells target deadly brain tumors in children
Disease control Recruiting nowThis study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell ther…
Phase 2 • Sponsor: BrainChild Bio, Inc • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Bladder cancer: a new combo aims to avoid radical surgery
Cure Not yet recruitingThis is a prospective, multicenter, randomized controlled superiority study designed to evaluate whether the addition of pelvic lymph node dissection improves bladder-intact event-free survival in patients with cT2-3N0M0 bladder urothelial carcinoma receiving bladder-sparing trea…
Phase 2/3 • Sponsor: Tianjin Medical University Second Hospital • Aim: Cure
Last updated Aug 12, 2026 00:00 UTC
-
Can engineered immune cells tackle a tough kidney disease?
Cure Not yet recruitingThis Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study…
Phase 1/2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug punch before surgery beat ALK-Positive lung cancer?
Cure Not yet recruitingThis is a single-arm clinical study planning to enroll 30 treatment-naive patients with resectable ALK-positive non-squamous non-small cell lung cancer (NSCLC). The study consists of two phases: a safety lead-in phase and an expansion phase. Safety Lead-in Phase A total of 6 sub…
Phase 2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Can a new triple therapy outsmart resistant myeloma?
Disease control Recruiting nowThe main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after previous treatment. The study will look at how long peop…
Phase 3 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a single gene edit stop kidney stones at the source?
Cure Recruiting nowThis is a single-arm, open-label, single-dose dose-escalation study. It aims to evaluate the safety and tolerability of YOLT-203 in Chinese patients with Primary Hyperoxaluria Type 1 (PH1), and to preliminarily assess the effect of a single administration of YOLT-203 on 24-hour u…
Phase 1 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
Cure Recruiting nowThis is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally advanced esophageal cancer. A total of 44 patients with …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Can a single shot build a cancer army inside the body?
Cure Not yet recruitingThis study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Phase 1/2 • Sponsor: Umoja Biopharma • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can a novel drug combo outperform standard chemo for lung cancer?
Disease control Not yet recruitingThis trial is a registrational randomized, open-label, multicenter Phase II/III study designed to evaluate the efficacy and safety of BL-B01D1 in combination with a PD-1/VEGF bispecific antibody in patients with locally advanced or metastatic non-squamous non-small cell lung canc…
Phase 2/3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can your own immune cells fight advanced cancer?
Cure Not yet recruitingA Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Cure
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill and injection combo beat AML without harsh chemo?
Cure Not yet recruitingAcute myeloid leukaemia (AML) is a clonal haematological malignancy characterised by arrested myeloid differentiation and uncontrolled proliferation of blast cells in the bone marrow and peripheral blood. It is the most common acute leukaemia in adults and carries a high disease-…
Phase 2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Could adding Clot-Busting drugs before surgery boost stroke recovery?
Disease control Not yet recruitingAcute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain. The TRACE-BRI…
Phase 3 • Sponsor: Yongjun Wang • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
Cure Recruiting nowThis study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX In…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Jul 22, 2026 00:00 UTC